Brazil and France partner on monitoring diseases in the Amazon border

29 October 2018
brazil-big

Border regions are especially sensitive to the transmission of diseases. Despite being used to stop people from crossing from one country to the other, they cannot prevent the dissemination of viruses and other infectious diseases, notes a posting on the website of the Fundação Oswaldo Cruz (Fiocruz).

In this context, Brazilian and French institutions have partnered to create an International Mixed Lab (LMI Sentinel), which will work to fight vector-borne diseases in Amazon border regions. LMI is an initiative of the French Research Institute for Development (IRD in French) together with Fiocruz, through the Instituto de Comunicação e Informação Científica e Tecnológica em Saúde - Icict/Fiocruz (Institute for Scientific and Technological Communication and Information on Health) with the support of Fiocruz Global Health Center (Cris-Fiocruz), and the Federal University of Brasília (UnB).

By using field research, geoprocessing, remote sensing and information technology, the project will start monitoring the relationship between climate change and malaria on the border between Amapá, in the North of Brasil, and French Guiana. The lab represents an opportunity to develop new technologies and methodologies, acting as a comprehensive information system that will gather data on the species of existing vectors, level of water in rivers, deforestation, urbanization, migrations, changes in the use of soil, among other things that influence disease transmission. Subsequently, the system will also cover surveillance of other vector-borne diseases, like zika, dengue and chikungunya, and other border regions, like the border between the state of Amazonas, Colombia and Peru.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical